Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466

Rebecca C. Arend; Angelina I. Londoño-Joshi; Abhishek Gangrade; Ashwini A. Katre; Chandrika Kurpad; Yonghe Li; Rajeev S. Samant; Pui Kai Li; Charles N. Landen; Eddy S. Yang; Bertha Hidalgo; Ronald D. Alvarez; John Michael Straughn; Andres Forero; Donald J. Buchsbaum

doi:10.18632/oncotarget.25151

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466

Rebecca C. Arend, Angelina I. Londoño-Joshi, Abhishek Gangrade, Ashwini A. Katre, Chandrika Kurpad, Yonghe Li, Rajeev S. Samant, Pui Kai Li, Charles N. Landen, Eddy S. Yang, Bertha Hidalgo, Ronald D. Alvarez, John Michael Straughn, Andres Forero, Donald J. Buchsbaum

Research output: Contribution to journal › Comment/debate

1 Scopus citations

Original language	English
Pages (from-to)	19459
Number of pages	1
Journal	Oncotarget
Volume	9
Issue number	27
DOIs	https://doi.org/10.18632/oncotarget.25151
State	Published - Apr 10 2018

Bibliographical note

Funding Information:
NIH grant support in the Comprehensive Flow Cytometry Core (CFCC) (P30 AR48311), Dr. Londono is funded by a NIH Research Training Program in Basic and Translation Oncology T32 Grant (T32CA183926). Dr. Arend is supported by the Foundation for Women's Cancer (WeRoc/OChO Ovarian Cancer Research Grant), Norma Livingston Foundation, AAOGF/ ABOG Career Development Award, and ACS-IRG (IRG-60-001-53-IRG). Dr. Hidalgo is supported by the NHLBI Diversity Supplement (HHSN268201300001) and a grant from the Robert Wood Johnson Foundation, New Connections Program.

Funding

NIH grant support in the Comprehensive Flow Cytometry Core (CFCC) (P30 AR48311), Dr. Londono is funded by a NIH Research Training Program in Basic and Translation Oncology T32 Grant (T32CA183926). Dr. Arend is supported by the Foundation for Women's Cancer (WeRoc/OChO Ovarian Cancer Research Grant), Norma Livingston Foundation, AAOGF/ ABOG Career Development Award, and ACS-IRG (IRG-60-001-53-IRG). Dr. Hidalgo is supported by the NHLBI Diversity Supplement (HHSN268201300001) and a grant from the Robert Wood Johnson Foundation, New Connections Program.

Funders	Funder number
AAOGF
ACS IRG 85-001-25	IRG-60-001-53-IRG
Norma Livingston Ovarian Cancer Foundation
National Institutes of Health (NIH)	P30 AR48311, T32CA183926
National Institutes of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)	HHSN268201300001
National Heart, Lung, and Blood Institute (NHLBI)
Robert Wood Johnson Foundation
Community Foundation of Calhoun County
Foundation for Women's Cancer
A Blade of Grass

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.18632/oncotarget.25151

Cite this

Arend, R. C., Londoño-Joshi, A. I., Gangrade, A., Katre, A. A., Kurpad, C., Li, Y., Samant, R. S., Li, P. K., Landen, C. N., Yang, E. S., Hidalgo, B., Alvarez, R. D., Straughn, J. M., Forero, A., & Buchsbaum, D. J. (2018). Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466. Oncotarget, 9(27), 19459. https://doi.org/10.18632/oncotarget.25151

@article{2c5d378c23f0476a94e2e6824da382a9,

title = "Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466",

author = "Arend, \{Rebecca C.\} and Londo{\~n}o-Joshi, \{Angelina I.\} and Abhishek Gangrade and Katre, \{Ashwini A.\} and Chandrika Kurpad and Yonghe Li and Samant, \{Rajeev S.\} and Li, \{Pui Kai\} and Landen, \{Charles N.\} and Yang, \{Eddy S.\} and Bertha Hidalgo and Alvarez, \{Ronald D.\} and Straughn, \{John Michael\} and Andres Forero and Buchsbaum, \{Donald J.\}",

note = "Funding Information: NIH grant support in the Comprehensive Flow Cytometry Core (CFCC) (P30 AR48311), Dr. Londono is funded by a NIH Research Training Program in Basic and Translation Oncology T32 Grant (T32CA183926). Dr. Arend is supported by the Foundation for Women's Cancer (WeRoc/OChO Ovarian Cancer Research Grant), Norma Livingston Foundation, AAOGF/ ABOG Career Development Award, and ACS-IRG (IRG-60-001-53-IRG). Dr. Hidalgo is supported by the NHLBI Diversity Supplement (HHSN268201300001) and a grant from the Robert Wood Johnson Foundation, New Connections Program.",

year = "2018",

month = apr,

day = "10",

doi = "10.18632/oncotarget.25151",

language = "English",

volume = "9",

pages = "19459",

number = "27",

}

Arend, RC, Londoño-Joshi, AI, Gangrade, A, Katre, AA, Kurpad, C, Li, Y, Samant, RS, Li, PK, Landen, CN, Yang, ES, Hidalgo, B, Alvarez, RD, Straughn, JM, Forero, A & Buchsbaum, DJ 2018, 'Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466', Oncotarget, vol. 9, no. 27, pp. 19459. https://doi.org/10.18632/oncotarget.25151

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466. / Arend, Rebecca C.; Londoño-Joshi, Angelina I.; Gangrade, Abhishek et al.
In: Oncotarget, Vol. 9, No. 27, 10.04.2018, p. 19459.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction

T2 - Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466

AU - Arend, Rebecca C.

AU - Londoño-Joshi, Angelina I.

AU - Gangrade, Abhishek

AU - Katre, Ashwini A.

AU - Kurpad, Chandrika

AU - Li, Yonghe

AU - Samant, Rajeev S.

AU - Li, Pui Kai

AU - Landen, Charles N.

AU - Yang, Eddy S.

AU - Hidalgo, Bertha

AU - Alvarez, Ronald D.

AU - Straughn, John Michael

AU - Forero, Andres

AU - Buchsbaum, Donald J.

N1 - Funding Information: NIH grant support in the Comprehensive Flow Cytometry Core (CFCC) (P30 AR48311), Dr. Londono is funded by a NIH Research Training Program in Basic and Translation Oncology T32 Grant (T32CA183926). Dr. Arend is supported by the Foundation for Women's Cancer (WeRoc/OChO Ovarian Cancer Research Grant), Norma Livingston Foundation, AAOGF/ ABOG Career Development Award, and ACS-IRG (IRG-60-001-53-IRG). Dr. Hidalgo is supported by the NHLBI Diversity Supplement (HHSN268201300001) and a grant from the Robert Wood Johnson Foundation, New Connections Program.

PY - 2018/4/10

Y1 - 2018/4/10

UR - http://www.scopus.com/inward/record.url?scp=85045193288&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045193288&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.25151

DO - 10.18632/oncotarget.25151

M3 - Comment/debate

C2 - 29721216

AN - SCOPUS:85045193288

SN - 1949-2553

VL - 9

SP - 19459

JO - Oncotarget

JF - Oncotarget

IS - 27

ER -

Correction: Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer [Oncotarget., 7, (2016) (86803-86815)] 10.18632/oncotarget.13466

Bibliographical note

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this